Arcellx (ACLX) Q2 Revenue Drops 72%

Arcellx (NASDAQ:ACLX), a biotechnology company developing cell therapies for blood cancers and autoimmune diseases, reported its second quarter 2025 results on August 7, 2025. The most notable update centered on a sharp revenue miss and a wider net loss, even as key clinical milestones advanced for its lead CAR-T cell therapy, anito-cel. Collaboration revenue (GAAP) was $7.6 million, falling short of analyst expectations of $13.52 million (GAAP). General and administrative expenses related to commercial readiness grew, while research and development expenses declined, driving the net loss (GAAP) to $52.8 million. The period was defined by a major data update from its pivotal clinical trial but also by financial pressures as the company transitions toward commercialization. Source: Analyst estimates for the quarter provided by FactSet. Arcellx develops therapies using its proprietary D-Domain technology, a synthetic binding scaffold designed to improve upon standard chimeric antigen receptor T cell (CAR-T) approaches. The company focuses on novel cell therapies for patients with relapsed or refractory multiple myeloma and is advancing other programs for autoimmune and solid tumor conditions.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool